Bridgebio Pharma SEC Filings

BridgeBio Pharma director Jennifer E. Cook received new equity compensation grants on June 20, 2025, consisting of:

• 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, bringing her total direct RSU ownership to 13,741 shares
• 8,425 Stock Options with an exercise price of $41.73 per share, expiring June 19, 2035

Both grants follow a 3-year vesting schedule with one-third vesting each year starting June 20, 2025, and completing on June 20, 2028. Vesting is contingent on Cook's continued service as a director. This Form 4 filing, signed on June 24, 2025, reflects standard equity compensation for non-employee directors and demonstrates the company's approach to aligning director interests with shareholders through long-term equity incentives.

BridgeBio Pharma Director Frank McCormick reported multiple equity transactions on June 20, 2025:

• Received 6,589 Restricted Stock Units (RSUs) with $0 exercise price, vesting over 3 years through June 20, 2028
• Granted 8,425 stock options with $41.73 exercise price, vesting over 3 years through June 20, 2028 and expiring June 19, 2035
• Currently holds 979,979 shares indirectly through the Francis P. McCormick Rev Trust

Both RSUs and options are subject to continued service on BridgeBio's board of directors. The grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting.

BridgeBio Pharma Director Eric Aguiar reported two significant equity transactions on June 20, 2025:

• Restricted Stock Units (RSUs): Acquired 6,589 RSUs at $0 cost, which vest over three years through June 20, 2028
• Stock Options: Received 8,425 options with exercise price of $41.73, vesting over three years and expiring June 19, 2035

Both grants are subject to Aguiar's continued service on BridgeBio's board of directors, with annual vesting of one-third of the awards. The RSUs represent contingent rights to receive common stock shares upon vesting. This compensation package aligns the director's interests with long-term shareholder value through a combination of time-based RSUs and options with a significant exercise price.

BridgeBio Pharma director Ronald J. Daniels received new equity compensation grants on June 20, 2025, consisting of:

• 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total direct RSU ownership to 16,991 units
• 8,425 Stock Options with an exercise price of $41.73 per share

Both grants follow a 3-year vesting schedule with one-third vesting annually from June 20, 2025 through June 20, 2028, contingent on continued board service. The stock options expire on June 19, 2035. These grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan, representing standard director compensation aligned with long-term shareholder interests.

BridgeBio Pharma Director Ali J. Satvat reported two significant equity transactions on June 20, 2025:

• Received 6,589 restricted stock units (RSUs) at $0, bringing total direct ownership to 165,993 shares. RSUs vest over three years through June 20, 2028
• Granted stock options to purchase 8,425 shares at an exercise price of $41.73 per share, expiring June 19, 2035

Both grants are subject to continued service on the board and follow a three-year vesting schedule, with one-third vesting each year starting June 20, 2025. The transactions were executed under the company's 2021 Amended and Restated Stock Option and Incentive Plan. Satvat serves as a Director but is not a 10% owner of BridgeBio Pharma.

BridgeBio Pharma director Charles J. Homcy received new equity compensation grants on June 20, 2025, consisting of:

• 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, vesting over 3 years through June 20, 2028
• 8,425 Stock Options with an exercise price of $41.73, vesting over 3 years through June 20, 2028

Following these transactions, Homcy directly owns 1,236,674 shares of common stock. Both the RSUs and stock options are subject to continued service on BridgeBio's board of directors. The grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan. This Form 4 filing represents standard board member equity compensation.

BridgeBio Pharma Director Fred Hassan received new equity compensation grants on June 20, 2025, consisting of:

• 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total direct ownership to 25,889 shares
• 8,425 Stock Options with an exercise price of $41.73 and expiration date of June 19, 2035

Both grants follow a 3-year vesting schedule with one-third vesting each year starting June 20, 2025, and completing on June 20, 2028. Vesting is contingent on Hassan's continued service as a director. The awards were granted under the company's 2021 Amended and Restated Stock Option and Incentive Plan. This Form 4 filing was signed on June 24, 2025, within the required reporting window.

BridgeBio Pharma Director Douglas A. Dachille reported multiple equity transactions on June 20, 2025:

• Received 6,589 restricted stock units (RSUs) with $0 exercise price, vesting over three years through June 20, 2028
• Granted 8,425 stock options with strike price of $41.73, vesting over three years and expiring June 19, 2035
• Currently holds 20,000 shares indirectly through The Dachille 2012-1 Family Trust for his children's benefit

All equity grants are subject to continued service on BridgeBio's board of directors. The RSUs and options will vest in three equal annual installments starting June 20, 2025. These grants appear to be part of the company's standard director compensation under their 2021 Amended and Restated Stock Option and Incentive Plan.